血清NSE和CA125作为小细胞肺癌疗效评价指标的临床价值

Clinical value of NSE and CA125 as an indicator of assessing therapeutic efficacy in small cell lung cancer

目的研究血清NSE和CA125作为小细胞肺癌(SCLC)疗效评价指标的价值。方法以NSE和(或)CA125升高的87例初治SCLC患者为研究对象,所有患者均采用化疗为主的治疗手段。按RECIST评价标准判断疗效,并分析治疗前后肿瘤标志物的变化与近期疗效的关系。结果部分缓解(PR)31例,稳定(SD)29例,进展(PD)27例。按肿瘤标志物的变化率分为下降组,升高组和稳定组,NSE下降组37例,升高组5例,稳定组31例;CA125下降组26例,升高组5例,稳定组14例。肿瘤标志物的变化率与影像学疗效评价显著相关。结论治疗前后NSE和CA125的变化可作为SCLC患者的影像学评价的预测指标。

Objective To investigate the value of NSE or CA125 as an indicator in assessing therapeutic efficacy in small cell lung cancer （SCLC） patients. Methods 87 cases of SCLC with chemotherapy were enrolled into this retrospective study. The serum NSE or CA125 levels of all patients were above the cut-off limit before treatment. The relationship between changes of tumor markers （TMs） and imaging therapeutic efficacy was analyzed. Result According to RECIST criteria, partial response （PR） occurred in 31 cases： stable disease （SD） in 29 and progressive disease （PD） in 27. The cut-off values of the changes of TMs between pre- and post-treatment were determined according to the above mentioned criteria. The NSE down, above, stable groups were 37, 5 and 31 cases, respectively. CA125 down, above, stable groups were 26 , 5 and 14 cases, respectively. Changes in serum tumor markers and imaging efficacy evaluation rate were significantly correlated （ rNSE = 0.52, PNSE = 0.00, rCA125 = 0. 44, PCA125 = 0. 00 ）. Conclusion NSE and CA125 before and after treatment changes in SCLC patients can be as a predictor of imaging evaluation.